The University of Chicago Header Logo

Markers of bone metabolism predict survival in hormone refractory prostate cancer (HRPC): Results from a randomized California Cancer Consortium & University of Chicago trial.

Markers of bone metabolism predict survival in hormone refractory prostate cancer (HRPC): Results from a randomized California Cancer Consortium & University of Chicago trial. J Clin Oncol. 2005 Jun; 23(16_suppl):4569.

View in: PubMed